Chairman: “Jeremy, welcome to the Board. What attracted you to...

Chairman: “Jeremy, welcome to the Board. What attracted
you to join Phylogica?”
Mr Curnock Cook: “I was particularly attracted to the
opportunity to develop Phylogica’s strategy, because it is not
often that one has the opportunity to help grow a company,
which controls global access to a new source of proprietary
therapeutics. This is an important period of transition for the
Company since it is only two years into the commercialisation
phase and as it continues to validate its technology, both
scientifically and through accumulating Pharma alliances. I
believe that if Phylogica continues on its current trajectory,
the Company will prove an attractive acquisition target for the
pharmaceutical industry.”

I like this industry veteran and new board member's confidence in PYC's phylomer library and associated technology's potential takeover value. One other similar company (Domantis, 2007) had been bought lock stock and two smoking barrels for many multiples of Market Capitalisation, despite no clinical candidates.

PYC has fairly proved itself a credible value package and I wouldnt be surprised about a purchase offer even before more major collaborations have been nailed down.

DYOR and go PYC